SAN FRANCISCO, CA – (July 29, 2025) – National plaintiffs law firm Lieff Cabraser Heimann & Bernstein, LLP encourages investors in Hims & Hers Health, Inc. (“Hims & Hers”) (NYSE: HIMS) who purchased or otherwise acquired Hims & Hers securities between April 29, 2025 and June 23, 2025, inclusive (the “Class Period”) to contact us immediately regarding pending securities class actions against Hims & Hers. The deadline to apply to be lead plaintiff is August 25, 2025.
Class Period: April 29, 2025 – June 23, 2025
Lead Plaintiff Motion Deadline: August 25, 2025
Case information: https://lieffcabraser.com/securities/hims/
Contact us: Email or text investorinfo@lchb.com or call 1-800-541-7358
Hims & Hers is an American telehealth company incorporated in Delaware and headquartered in San Francisco, California. On April 29, 2025, Hims & Hers announced a long-term collaboration with Novo Nordisk, centered around “a bundled offering of Novo Nordisk’s Food & Drug Administration (“FDA”)-approved Wegovy® on the Hims & Hers platform.” Wegovy is a form of compounded semaglutide used for weight-loss.
The actions allege that, throughout the Class Period, Defendants made false and/or misleading statements and/or failed to disclose that: (1) Hims & Hers was promoting and selling “illegitimate, knockoff versions of Wegovy” which endangered patients; and (2) as a result, there was a substantial risk that Hims & Hers’ recently announced partnership with Novo Nordisk would be terminated.
On June 23, 2025, Novo Nordisk announced that it was terminating its collaboration with the Company on account of Hims & Hers’ (1) “deceptive promotion and selling of illegitimate, knockoff versions of Wegovy® that put patient safety at risk” as the compounded semaglutide is manufactured by foreign suppliers in China not approved or regulated by the FDA, and may contain dangerous and illicit ingredients; and (2) failure to follow the law “prohibit[ing] mass sales of compounded drugs under the false guise of ‘personalization’.” On this news, the price of Hims & Hers common stock fell $22.24 per share, or 34.6%, from its closing price of $64.22 per share on June 20, 2025 to close at $41.98 per share on June 23, 2025.
About Lieff Cabraser
Lieff Cabraser Heimann & Bernstein, LLP, with over 125 attorneys in offices in San Francisco, New York, Nashville, and Munich, Germany, is an internationally-recognized law firm committed to advancing the rights of investors and promoting corporate responsibility. Repeatedly recognized as a “Plaintiffs’ Powerhouse” by Law360, Lieff Cabraser has litigated some of the most important civil cases in the United States, and has assisted clients in recovering over $131 billion in verdicts and settlements. For over 50 years, Lieff Cabraser has remained committed to ensuring access to justice for all.
Source/Contact
Sharon Lee
Lieff Cabraser Heimann & Bernstein, LLP
415 956-1000
slee@lchb.com
Contact us
Use the form below to contact a lawyer at Lieff Cabraser.
